Alzheimer's Disease Viewed as a Neurovascular Inflammatory Disorder

阿尔茨海默病被视为一种神经血管炎症性疾病

基本信息

批准号：
9195011
负责人：
Costantino Iadecola
金额：
$ 1.5万
依托单位：
NEW YORK ACADEMY OF SCIENCES
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-12-06 至 2017-12-05
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9195011
关键词：
Academia Academy Address Age Alzheimer&apos s Disease Amyloid Animal Model Area Awards and Prizes Basic Science Biological Markers Biology Blood - brain barrier anatomy Blood Vessels Brain Cerebral Amyloid Angiopathy Cerebrovascular Disorders Child Care Clinical Clinical Sciences Clinical Trials Collaborations Communication Communities Data Dementia Developing Countries Development Disabled Persons Disease Disease Progression Ensure Environment Etiology Event Faculty Family Fellowship Female Fostering Foundations Functional disorder Future Genetic Goals Government Head Health Healthcare Systems Human Image Immune response Impaired cognition Impairment Industry Inflammation Inflammatory International Knowledge Label Life Link Maps Medical Research Microvascular Dysfunction Molecular Molecular Target Monitor National Institute of Neurological Disorders and Stroke Neurodegenerative Disorders Neurons New York Nonprofit Organizations Onset of illness Oral Participant Pathology Patients Persons Physiological Processes Population Prevention Prize Process Publications Publishing Research Research Personnel Risk Factors Role Science Stroke Study models Technology Testing Translating Translations Travel Underrepresented Minority Update Vascular Dementia Vascular Diseases Woman Work abstracting aging population base biomarker identification career data exchange discount effective therapy genetic information global health health economics improved insight interdisciplinary approach knowledge base meetings minority investigator neuropathology neurovascular new therapeutic target novel patient population posters pre-clinical prevent racial minority repository socioeconomics symposium therapeutic target tool vascular contributions vascular inflammation webinar

Academia Academy Address Age Alzheimer&apos s Disease Amyloid Animal Model Area Awards and Prizes Basic Science Biological Markers Biology Blood - brain barrier anatomy Blood Vessels Brain Cerebral Amyloid Angiopathy Cerebrovascular Disorders Child Care Clinical Clinical Sciences Clinical Trials Collaborations Communication Communities Data Dementia Developing Countries Development Disabled Persons Disease Disease Progression Ensure Environment Etiology Event Faculty Family Fellowship Female Fostering Foundations Functional disorder Future Genetic Goals Government Head Health Healthcare Systems Human Image Immune response Impaired cognition Impairment Industry Inflammation Inflammatory International Knowledge Label Life Link Maps Medical Research Microvascular Dysfunction Molecular Molecular Target Monitor National Institute of Neurological Disorders and Stroke Neurodegenerative Disorders Neurons New York Nonprofit Organizations Onset of illness Oral Participant Pathology Patients Persons Physiological Processes Population Prevention Prize Process Publications Publishing Research Research Personnel Risk Factors Role Science Stroke Study models Technology Testing Translating Translations Travel Underrepresented Minority Update Vascular Dementia Vascular Diseases Woman Work abstracting aging population base biomarker identification career data exchange discount effective therapy genetic information global health health economics improved insight interdisciplinary approach knowledge base meetings minority investigator neuropathology neurovascular new therapeutic target novel patient population posters pre-clinical prevent racial minority repository socioeconomics symposium therapeutic target tool vascular contributions vascular inflammation webinar

展开

项目摘要

Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder PROJECT SUMMARY / ABSTRACT Alzheimer’s disease (AD) is a devastating neurodegenerative disorder lacking effective treatments. Most clinical trials testing the long-standing amyloid hypothesis of AD have shown little promise. The future of novel treatments targeting other pathophysiological processes in the disease is uncertain. Growing evidence supports a role for neurovascular inflammation as a major causative or exacerbating factor in AD onset and progression. However, the scientific community has yet to label AD a vascular disease and questions remain about the viability of neurovascular inflammation as a potential therapeutic target. To address this controversy head-on, the New York Academy of Sciences will present a 1-day symposium and simulcast Webinar, “Alzheimer’s Disease Viewed as a Neurovascular Inflammatory Disorder” on 12/6/2016. The goal of this symposium is to evaluate clinical and preclinical data investigating the role of neurovascular pathology in the development of AD. Critical barriers to understanding how to clinically test vascular-based hypotheses for the treatment of AD will be discussed, including recent imaging advances for monitoring disease progression. Moreover, emerging science on molecular and physiological processes that can be leveraged as targets for novel therapeutics will be presented. This symposium will fill an important gap in the conference landscape, presenting a focused, in-depth discussion on the synergies between AD and vascular disease research, building upon the recently defined need to better understand neurovascular dysregulation in AD and vascular dementia (36). This landmark event will unite 200 in-person basic, translational, and clinical researchers — along with a global audience of Webinar participants — from academia, industry, government, and non-profit organizations, working on neurodegenerative disorders and vascular disease in an effort to understand, prevent, and treat AD and vascular dementias such as small vessel disease (SVD). Sessions will address 5 central aims: (i) Elucidate the relationship between genetic information and neurovascular pathology in AD and SVD; (ii) Explore novel molecular targets and physiological processes critical to vascular function and CNS health, using human studies and animal models; (iii) Describe clinical aspects of neurovascular dysregulation and inflammation in AD and SVD and identify biomarkers for vascular-based mechanisms; (iv) Identify knowledge gaps and future research required for breakthroughs in prevention and treatment of AD; and (v) Showcase and encourage the participation of Early-Career, female, and Underrepresented Minority investigators via short talks, poster presentations and prizes, travel fellowships, and discounted registration. In addition, the NINDS’ specific goal of disseminating information will be met through a simulcast Webinar and publication of an enduring open-access Academy eBriefing. A collaborative, multidisciplinary approach will be critical to meeting the urgent unmet need for AD patients. To that end, this event will consider new disease mechanisms and therapeutic targets for AD, from a broad range of perspectives.

阿尔茨海默氏病被视为神经血管炎症疾病项目摘要 /摘要阿尔茨海默氏病（AD）是缺乏有效治疗的毁灭性神经退行性疾病。最多临床试验测试长期的AD淀粉样假说几乎没有任何希望。小说的未来针对疾病中其他病理生理过程的治疗尚不确定。越来越多的证据支持神经血管炎症作为AD发作中的主要结构或加剧因素的作用进展。但是，科学界尚未标记为血管疾病的标签，问题仍然存在关于神经血管炎症作为潜在的治疗靶点的生存能力。解决这一争议纽约科学院直接将举行为期1天的研讨会和Simulcast网络研讨会， 2016年12月6日，“阿尔茨海默氏病被视为神经血管炎症疾病”。目标的目标研讨会是评估临床和临床前数据研究神经血管病理在广告的开发。了解如何在临床上测试基于血管的假设的关键障碍将讨论AD的治疗，包括最近监测疾病进展的成像进展。此外，关于分子和物理过程的新兴科学，可以将其作为目标的目标新颖的理论将被提出。该研讨会将填补会议景观中的重要空白，就AD和血管疾病研究之间的协同作用进行了重点，深入的讨论，在最近定义的基础上，需要更好地了解AD和血管中的神经血管失调痴呆症（36）。这项具有里程碑意义的活动将团结200个面对面的基础，翻译和临床研究人员 - 以及来自学术界，工业，政府和非营利组织的全球网络研讨会参与者的观众组织，致力于神经退行性疾病和血管疾病，以理解，预防和治疗AD和血管痴呆，例如小血管疾病（SVD）。会议将解决 5中心目的：（i）阐明AD中遗传信息与神经血管病理之间的关系和SVD；（ii）探索对血管功能至关重要的新型分子靶标和物理过程健康，使用人类研究和动物模型；（iii）描述神经血管失调的临床方面和AD和SVD中的炎症，并确定基于血管机制的生物标志物；（iv）识别在预防和治疗AD方面取得突破所需的知识差距和未来的研究；（v）展示并鼓励早期职业，女性和代表性不足的少数民族参与调查人员通过简短的会谈，海报演示和价格，旅行奖学金和折扣注册。此外，Ninds将通过Simulcast网络研讨会实现传播信息的具体目标以及持久的开放学院学院的启用。合作，多学科方法对于满足AD患者的紧急需求至关重要。为此，此事件将从广泛的角度考虑新的疾病机制和AD的治疗靶标。